Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma

BMC Research Notes

Kikuo Nutahara²  Eiji Higashihara²  Mitsuhiro Tambo²  Yuichi Terado¹  Takatsugu Okegawa²  Naoyuki Fujita² 

[1]Departments of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, Japan

[2]Departments of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, Japan

关键词: Nephrectomy;    Vascular endothelial growth factor;    Renal cell carcinoma;    Recurrence;   

Others  :  1132471
DOI  :  10.1186/1756-0500-7-369

 received in 2013-07-06, accepted in 2014-06-11,  发布年份 2014

【 摘 要 】

Background

Vascular endothelial growth factor (VEGF) plays a major role in angiogenesis. One of the functions of VEGF is to regulate neovascularization in clear cell renal cell carcinoma (CCRCC). The objective of our study was to examine whether before nephrectomy serum levels of VEGF or expression of VEGF using immunohistochemistry (IHC) could predict postoperative recurrence in nonmetastatic CCRCC.

Results

Twelve patients (14.5%) had recurrence during a mean follow-up of 52.6 ± 31.2 months. The serum VEGF level was significantly higher in patients with recurrence than in those without recurrence (P = 0.038). High serum VEGF levels were above 416 pg/mL; this value was chosen based on a receiver operating characteristic analysis. The recurrence-free survival rate in patients with a high serum VEGF level was significantly lower than in those with a low serum VEGF level (P = 0.003). In total, tumors from 26 patients (31.3%) showed overexpression of VEGF using IHC. The recurrence-free survival rate in the IHC-positive group was significantly lower than that in the IHC-negative group (P = 0.044). Multivariate analysis indicated that preoperative serum VEGF levels (P = 0.013) and female gender (P = 0.004) were independent predictors of postoperative recurrence in nonmetastatic CCRCC.

Conclusions

Preoperative serum VEGF levels is a useful predictor compared with IHC analysis of VEGF of postoperative recurrence in nonmetastatic CCRCC.

【 授权许可】

   
2014 Fujita et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal cell carcinoma. Clin Canc Res 2007, 13:680-684.
• [2]Brugarolas J: Renal cell carcinoma–molecular pathways and therapies. N Engl J Med 2007, 356:185-187.
• [3]Herbst RS: Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 2006, 11:635-650.
• [4]Li G, Feng G, Gentil-Perret A, Genin C, Tostain J: Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell carcinoma. J Urol 2008, 180:510-513.
• [5]Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS: Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Canc Epidemiol Biomarker Prev 2009, 18:894-900.
• [6]Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343-347.
• [7]Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, Benoît G, Jardin A, Bedossa P: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000, 436:351-356.
• [8]Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY: Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 2004, 93:1087-1093.
• [9]Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E: Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor. Nihon Hinyokika Gakkai Zasshi 2013, 104:1-5. (in Japanese)
• [10]Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
• [11]Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.
• [12]Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008, 101:959-963.
• [13]Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143:1255-1262.
• [14]Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux BC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
• [15]Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
• [16]Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, Epstein JI, Patard JJ: Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007, 38:1489-1495.
• [17]Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T: Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Clin Res 1999, 90:874-879.
• [18]Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
• [19]Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
• [20]Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000, 58:169-174.
• [21]Werther K, Christensen IJ, Nielsen HJ: Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002, 62:343-350.
• [22]Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH: Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating Vascular endothelial growth factor. Angiogenesis 2003, 6:283-287.
• [23]Niers TM, Richel DJ, Meijers JC, Schlingemann RO: Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 2011, 6:e19873.
• [24]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
• [25]Tanimoto S, Fukumori T, EI-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO: Prognostic significance of serum hepatocyte growth factor in clear cell renal carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest 2008, 55:106-111.
• [26]Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R: The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010, 75:608-614.
• [27]Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671.
• [28]Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A: Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000, 163:426-430.
• [29]Kimura H, Kato H, Tanaka N, Inose T, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Manda R, Fukuchi M, Ojima H, Tsukada K, Kuwano H: Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008, 28:165-169.
• [30]Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J: Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients. Dis Colon Rectum 2009, 52:993-999.
• [31]Zhong C, Wei W, Su XK, Li HD, Xu FB, Guo RP: Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepatogastroenterology 2012, 59:93-97.